Insulin-like growth factor (IGF)-I has proven to be important in the diagnosis of childhood-onset growth hormone (GH) deficiency (GHD). However, the variability of IGF-I should be taken into account before it can be used in a clinical setting. GH replacement therapy in GHD patients increases IGF-I into the normal range, although there is a large variation. Excessively high (supranormal) GH-induced IGF-I levels are associated with increased prevalence of side effects in adults with GHD. Consequently, at most centres, GH doses are titrated according to IGF-I levels in GHD adults. Whether or not this should also be done in children has not been established. Due to the known variability of IGF-I, individual changes in IGF-I must exceed approximately 35% to be sufficiently significant to warrant a dose adjustment. Novel epidemiological studies have suggested that higher IGF-I levels are associated with an increased risk of prostate, breast and colorectal cancer compared with lower IGF-I levels in otherwise healthy subjects. Consequently, life-time exposure to IGF-I should be considered in all patients treated with GH, and IGF-I should preferably be kept within normal age-related ranges in children as well as in adults.

Keywords:
Insulin-like growth factor-I, Growth hormone, Diagnosis, Monitoring GH treatment, GH deficiency, Cancer risk, Cardiovascular disease, Variation
1.
Guler H-P, Zapf J, Schmid C, Froesch ER: Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. Acta Endocrinol 1989;121:753–758.
2.
Giudice LC, Farrell EM, Pham H, Lamson G, Rosenfeld RG: Insulin-like growth factor binding proteins in maternal serum throughout gestation and in the puerperium: effects of a pregnancy-associated serum protease activity. J Clin Endocrinol Metab 1990;71:806–816.
3.
Lassarre C, Binoux M: Insulin-like growth factor binding protein-3 is functionally altered in pregnancy plasma. Endocrinology 1994;134:1254–1262.
4.
Suikkari A-M, Baxter RC: Insulin-like growth factor- binding protein-3 is functionally normal in pregnancy serum. J Clin Endocrinol Metab 1992;74:177–183.
5.
Davies SC, Wass JAH, Ross RJM, Cotterill AM, Buchanan CR, Coulson VJ, Holly JMP: The induction of a specific protease for insulin-like growth factor binding protein-3 in the circulation during severe illness. J Endocrinol 1991;130:469–473.
6.
Davenport ML, Isley WL, Pucilowska JB, Pemberton LB, Lyman B, Underwood LE, Clemmons DR: Insulin-like growth factor- binding protein-3 proteolysis is induced after elective surgery. J Clin Endocrinol Metab 1992;75:590–595.
7.
Skjærbæk C, Frystyk J, Ørskov H, Kissmeyer-Nielsen P, Jensen MB, Laurberg S, Møller N, Flyvbjerg A: Differential changes in free and total insulin-like growth factor I after major, elective abdominal surgery: the possible role of insulin-like growth factor binding protein-3 proteolysis. J Clin Endocrinol Metab 1998;83:2445–2449.
8.
Bang P, Nygren J, Carlsson-Skwirut C, Thorell A, Ljungqvist O: Postoperative induction of insulin-like growth factor binding protein-3 proteolytic activity: relation to insulin and insulin sensitivity. J Clin Endocrinol Metab 1998;83:2509–2515.
9.
Hughes SCC, Cotterill AM, Molloy AR, Cassell TB, Braude N, Hinds CJ, Wass JAH, Holly JMP: The induction of specific proteases for insulin-like growth factor-binding proteins following major heart surgery. J Endocrinol 1992;135:135–145.
10.
Rose SR, Ross JL, Uriarte M, Barnes KM, Cassorla FG, Cutler GBJ: The advantage of measuring stimulated as compared with spontaneous growth hormone levels in the diagnosis of growth hormone deficiency. N Engl J Med 1988;319(4):201–207.
11.
Blum WF, Albertsson-Wikland K, Rosberg S, Ranke MB: Serum levels of insulin-like growth factor I (IGF-I) and IGF binding protein 3 reflect spontaneous growth hormone secretion. J Clin Endocrinol Metab 1993;76:1610–1616.
12.
Nunez SB, Municchi G, Barnes KM, Rose SR: Insulin-like growth factor I (IGF-I) and IGF binding protein-3 concentrations compared to stimulated and night growth hormone in the evaluation of short children – a clinical research center study. J Clin Endocrinol Metab 1996;81:1927–1932.
13.
Oerter KE, Sobel AM, Rose SR, Cristiano A, Malley JD, Cutler GB Jr, Baron J: Combining insulin-like growth factor-I and mean spontaneous nighttime growth hormone levels for the diagnosis of growth hormone deficiency. J Clin Endocrinol Metab 1992;75:1413–1420.
14.
Vahl N, Jørgensen JOL, Jurik AG, Christiansen JS: Abdominal adiposity and physical fitness are major determinants of the age associated decline in stimulated GH secretion in healthy adults. J Clin Endocrinol Metab 1996;81:2209–2215.
15.
Baum HBA, Biller MK, Katznelson L, Oppenheim DS, Clemmons DR, Cannistraro KB, Schoenfeld DA, Best SA, Klibanski A: Assessment of growth hormone (GH) secretion in men with adult-onset GH deficiency compared with that in normal men – a clinical research center study. J Clin Endocrinol Metab 1996;81:84–92.
16.
Corpas E, Harman SM, Blackman MR: Serum IGF-binding protein-3 is related to IGF-I, but not to spontaneous GH release, in healthy old men. Horm Metab Res 1992;24:543–545.
17.
Reutens AT, Hoffman DM, Leung K-C, Ho KKY: Evaluation and application of a highly sensitive assay for serum growth hormone (GH) in the study of adult GH deficiency. J Clin Endocrinol Metab 1995;80:480–485.
18.
Juul A, Bang P, Hertel NT, Main K, Dalgaard P, Jørgensen K, Müller J, Hall K, Skakkebæk NE: Serum insulin-like growth factor-1 in 1030 healthy children, adolescents and adults; relation to age, sex, stage of puberty, testicular size and body mass index. J Clin Endocrinol Metab 1994;78:744–752.
19.
Juul A, Møller S, Mosfeldt-Laursen E, Rasmussen MH, Scheike T, Pedersen SA, Kastrup KW, Yu H, Mistry J, Rasmussen S, Müller J, Henriksen J, Skakkebæk NE: The acid- labile subunit of human ternary insulin-like growth factor binding protein complex in serum: hepatosplanchnic release, diurnal variation, circulating concentrations in healthy subjects, and diagnostic use in patients with growth hormone deficiency. J Clin Endocrinol Metab. In press.
20.
Oscarsson J, Johannsson G, Johansson J-O, Lundberg P-A, Lindstedt G, Bengtsson B-Å: Diurnal variation in serum insulin-like growth factor (IGF)-I and IGF binding protein-3 concentrations during daily subcutaneous injections of recombinant human growth hormone in GH-deficient adults. Clin Endocrinol 1997;46:63–68.
21.
Juul A, Scheike T, Pedersen AT, Main KM, Andersson A-M, Pedersen LM, Skakkebæk NE: Changes in serum concentrations of growth hormone, insulin, insulin-like growth factor and insulin-like growth factor binding proteins 1 and 3 and urinary GH excretion during the menstrual cycle. Hum Reprod 1997;12:2123–2128.
22.
Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563.
23.
Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393–1396.
24.
Bang P, Eriksson U, Sara V, Wivall I-L, Hall K: Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta Endocrinol 1991;124:620–629.
25.
Blum WF, Ranke MB, Bierich JR: A specific radioimmunoassay for insulin-like growth factor II: the interference of IGF binding proteins can be blocked by excess IGF-I. Acta Endocrinol 1988;118:374–380.
26.
Quarmby V, Quan C, Ling V, Compton P, Canova-Davis E: How much insulin-like growth factor I (IGF-I) circulates? Impact of standardization on IGF-I assay accuracy. J Clin Endocrinol Metab 1998;83:1211–1216.
27.
Baxter RC, Cowell CT: Diurnal rhythm of growth hormone-independent binding protein for insulin-like growth factors in human plasma. J Clin Endocrinol Metab 1987;65:432–440.
28.
Buzzelli G, Dattolo P, Pinzani M, Brocchi A, Romano S, Gentilini P: Circulating growth hormone and insulin-like growth factor-I in nonalcoholic liver cirrhosis with or without superimposed hepatocarcinoma: evidence of an altered circadian rhythm. Am J Gastroenterol 1993;88:1744–1748.
29.
Caufriez A, Golstein J, Tadjerouni A, Bosson D, Cantraine F, Robyn C, Copinschi G: Modulation of immunoreactive somatomedin-C levels by sex steroids. Acta Endocrinol 1986;112:284–289.
30.
Toogood AA, Jones J, O’Neill PA, Thorner MO, Shalet SM: The diagnosis of severe growth hormone deficiency in elderly patients with hypothalamic-pituitary disease. Clin Endocrinol 1998;48:569–576.
31.
Nikolic JA, Nedic O, Ratkavic M, Masnikosa R: Alterations in serum insulin-like growth factor (IGF-I) levels during the menstrual cycle. Jugoslav Med Biochem 1998;17:15–20.
32.
Ovesen P, Vahl N, Fisker S, Veldhuis JD, Christiansen JS, Jørgensen JOL: Increased pulsatile, but not basal, growth hormone secretion rates and plasma insulin-like growth factor I levels during the periovulatory interval in normal women. J Clin Endocrinol Metab 1998;83:1662–1667.
33.
Wang H-S, Lee JD, Soong Y-K: Serum levels of insulin-like growth factor I and insulin-like growth factor-binding protein-1 and -3 in women with regular menstrual cycles. Fertil Steril 1995;63:1204–1209.
34.
Thierry van Dessel HJHM, Chandrasekher Y, Yap OWS, Lee PDK, Hintz RL, Faessen GHJ, Braat DDM, Fauser BCJM, Giudice LC: Serum and follicular fluid levels of insulin-like growth factor I (IGF-I), IGF-II and IGF-binding proteins-1 and -3 during the normal menstrual cycle. J Clin Endocrinol Metab 1996;81:1224–1231.
35.
Holdaway IM, Mason BH, Gibbs EE, Rajasoorya C, Lethaby A, Hopkins KD, Evans MC, Lim T, Schooler B: Seasonal variation in the secretion of mammotrophic hormones in normal woman and women with previous breast cancer. Breast Cancer Res Treat 1997;42:15–22.
36.
Gelander L, Larsson L, Rosberg S, Albertsson-Wikland K: Changes in serum concentrations of insulin-like growth factor I and insulin-like growth factor binding protein-3: when are they significant? Acta Pædiatr Suppl 1997;423:143.
37.
Juul A, Scheike T, Nielsen CT, Krabbe S, Müller J, Skakkebæk NE: Serum insulin-like growth factor (IGF)-I and IGF binding protein-3 levels are increased in central precocious puberty: effects of two different treatment regimens with GnRH agonists, without or in combination with an anti-androgen (cyproterone acetate). J Clin Endocrinol Metab 1995;80:3059–3067.
38.
Ravn P, Overgaard K, Spencer EM, Christiansen C: Insulin- like growth factors I and II in healthy women with and without established osteoporosis. Eur J Endocrinol 1995;132:313–319.
39.
Weissberger AJ, Ho KKY, Lazarus L: Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab 1991;72:347–381.
40.
Kelly JJ, Rajkovic IA, O’Sullivan AJ, Sernia C, Ho KKY: Effects of different oral oestrogen formulations on insulin-like growth factor-I, growth hormone and growth hormone binding protein in post-menopausal women. Clin Endocrinol 1993;39:561–567.
41.
Slowinska-Srzednicka J, Zgliczynski S, Jeske W, Stopinska- Gluszak U, Srzednicki M, Brzezinska A, Zgliczynski W, Sadowski Z: Transdermal 17-estradiol combined with oral progestogen increases plasma levels of insulin-like growth factor-I in postmenopausal women. J Endocrinol Invest 1992;15:553–558.
42.
Parker MW, Johanson AJ, Rogol AD, Kaiser DL, Blizzard RM: Effect of testosterone on somatomedin-C concentrations in prepubertal boys. J Clin Endocrinol Metab 1984;58:87–90.
43.
Hobbs CJ, Plymate SR, Rosen CJ, Adler RA: Testosterone administration increases insulin-like growth factor-I levels in normal men. J Clin Endocrinol Metab 1993;77:776–779.
44.
Veldhuis JD, Metzger DL, Martha PM, Mauras N, Kerrigan JR, Keenan B, Rogol AD, Pincus SM: Estrogen, and testosterone, but a nonaromatizable androgen, direct network integration of the hypothalamo-somatotrope (growth hormone)-insulin-like growth factor I axis in the human: evidence from pubertal pathophysiology and sex steroid hormone replacement. J Clin Endocrinol Metab 1997;82:3414–3420.
45.
Wolf OT, Neumann O, Hellhammer DH, Geiben AC, Strasburger CJ, Dressendörfer RA, Pirke K-M, Kirschbaum C: Effects of a two-week physiological dehydroepiandrosterone substitution on cognitive function and well-being in healthy elderly women and men. J Clin Endocrinol Metab 1997;82:2363–2367.
46.
Holt RIG, Jones JS, Stone NM, Baker AJ, Miell JP: Sequential changes in insulin-like growth factor I (IGF-I) and IGF-binding proteins in children with end-stage liver disease before and after successful orthotopic liver transplantation. J Clin Endocrinol Metab 1996;81:160–168.
47.
Shaarawy M, Fikry MA, Massoud BM, Lotfy S: Insulin-like growth factor binding protein-3: a novel biomarker for the assessment of the synthetic capacity of hepatocytes in liver cirrhosis. J Clin Endocrinol Metab 1998;83:3316–3319.
48.
Buzi F, Bontempelli AM, Alberti D, Jones J, Pilotta A, Lombardi A, Guistina A, Preece MA: Growth, insulin-like growth factor I (IGF-I), and IGF-binding proteins 1 and 3 in children with severe liver disease before and after liver transplantation: a longitudinal and cross-sectional study. Pediatr Res 1998;43:478–483.
49.
Møller S, Juul A, Becker U, Flyvbjerg A, Skakkebæk NE, Henriksen JH: Concentrations, release and disposal of insulin-like growth factor binding proteins (IGFBP), insulin-like growth factor-I (IGF-I), and growth hormone (GH) in different vascular beds in patients with cirrhosis. J Clin Endocrinol Metab 1995;80:1148–1157.
50.
Hokken-Koelega ACS, Hackeng WHL, Stijnen T, Wit JM, Keizer-Schrama SMPFD, Drop SLS: Twenty-four-hour plasma growth hormone (GH) profiles, urinary GH excretion, and plasma insulin-like growth factor-I and -II levels in prepubertal children with chronic renal insufficiency and severe growth retardation. J Clin Endocrinol Metab 1990;71:688–695.
51.
Tönshoff B, Blum WF, Wingen A-M, Mehls O: Serum insulin- like growth factors (IGFs) and IGF binding proteins 1, 2 and 3 in children with chronic renal failure: relationship to height and glomerular filtration rate. J Clin Endocrinol Metab 1995;80:2684–2691.
52.
Blum WF, Ranke MB, Kietzmann K, Tönshoff B, Mehls O: Growth hormone resistance and inhibition of somatomedin activity by excess of insulin-like growth factor binding protein in uraemia. Pediatr Nephrol 1991;5:539–544.
53.
Thissen J-P, Ketelslegers J-M, Underwood LE: Nutritional regulation of the insulin-like growth factors. Endocr Rev 1994;15:80–101.
54.
Laursen EM, Juul A, Lanng S, Høiby N, Koch C, Skakkebæk NE: Diminished levels of insulin-like growth factor I (IGF- I) in patients with cystic fibrosis. Arch Dis Child 1995;72:494–497.
55.
Wabitsch M, Blum WF, Muche R, Heinze E, Haug C, Mayer H, Teller W: Insulin-like growth factors and their binding proteins before and after weight loss and their associations with hormonal and metabolic parameters in obese adolescent girls. Int J Obesity Relat Metab Disord 1996;20:1073–1080.
56.
Rasmussen MH, Hvidberg A, Juul A, Main KM, Gotfredsen A, Skakkebæk NE, Hilsted J: Massive weight loss restores 24-hour growth hormone release profiles and serum insulin-like growth factor-I in obese subjects. J Clin Endocrinol Metab 1995;80:1407–1415.
57.
Rosén T, Bengtsson B-Å: Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990;336:285–288.
58.
Cummings MH, Christ E, Umpleby AM, Albany E, Wierbicki A, Lumb PJ, Sönksen PH, Russell-Jones DL: Abnormalities of very low density lipoprotein apolipoprotein B-100 metabolism contribute to the dyslipidemia of adult growth hormone deficiency. J Clin Endocrinol Metab 1997;82:2010–2014.
59.
Al-Shoumer KAS, Cox KH, Hughes CL, Richmond W, Johnston DG: Fasting and postprandial lipid abnormalities in hypopituitary women receiving conventional replacement therapy. J Clin Endocrinol Metab 1997;82:2653–2659.
60.
Shahi M, Beshyah SA, Hackett D, Sharp PS, Johnston DG, Foale RA: Myocardial dysfunction in treated adult hypopituitarism: A possible explanation for increased cardiovascular mortality. Br Heart J 1992;67:92–96.
61.
Merole B, Cittadini A, Colao A, Longobardi S, Fazio S, Sabatini D, Saccà L, Lombardi G: Cardiac structural and functional abnormalities in adult patients with growth hormone deficiency. J Clin Endocrinol Metab 1993;77:1658–1661.
62.
Cittadini A, Cuocolo A, Merola B, Fazio S, Sabatini D, Nicolai E, Colao A, Longobardi S, Lombardi S, Saccà L: Impaired cardiac performance in GH-deficient adults and its improvement after GH replacement. Am J Physiol 1994;267:E219–E225.
63.
Capaldo B, Patti L, Oliviero U, Longobardi S, Pardo F, Vitale F, Fazio S, di Rella F, Biondi B, Lombardi G, Saccà L: Increased arterial intima-media thickness in childhood-onset growth hormone deficiency. J Clin Endocrinol Metab 1997;82:1378–1381.
64.
Lehman ED, Hopkin KD, Weissberger AJ, Gosling RG, Sönksen PH: Aortic distensibility in growth hormone deficient adults. Lancet 1993;341:309.
65.
Markussis V, Beshyah SA, Fisher C, Sharp P, Nicolaides AN, Johnston DG: Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults. Lancet 1992;340:1188–1192.
66.
Hopkins KD, Lehmann ED, Gosling RG, Parker JR, Sönksen PH: Biochemical correlates of aortic distensibility in vivo in normal subjects. Clin Sci 1993;84:593–597.
67.
Diez J, Laviades C, Mayor G: Effects of antihypertensive therapy on left ventricular hypertrophy of essential hypertension: A role for insulin-like growth factor I? J Hum Hypertens 1993;7:484.
68.
Cheung NW, Boyages SC: Increased incidence of neoplasia in females with acromegaly. Clin Endocrinol 1997;47:323–327.
69.
Ladas SD, Thalassinos NC, Ioannides G, Raptis SA: Does acromegaly really predispose to an increased prevalence of gastrointestinal tumours? Clin Endocrinol 1994;41:597–601.
70.
Barni S, Lissoni P, Brivio F, Fumagalli L, Merlini D, Cataldo M, Rovelli F, Tancini G: Serum levels of insulin-like growth factor-I in operable breast cancer in relation to the main prognostic variables and their perioperative changes in relation to those of prolactin. Tumori 1994;80:212–215.
71.
Yu H, Levesque MA, Khoshravi MJ, Papanastasiou-Diamandi A, Clark GM, Diamandis EP: Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer. Br J Cancer 1996;74:1242–1247.
72.
Ng E-H, Ji C-Y, Tan P-H, Lin V, Soo K-C, Lee K-O: Altered serum levels of insulin-like growth factor binding proteins in breast cancer patients. Ann Surg Oncol 1998;5:194–201.
73.
Brunning PE, van Doorn J, Bonfrer JMG, van Noord PAH, Korse CM, Lindres TC, Hart AAM: Insulin-like growth factor binding protein 3 is decreased in early-stage operable pre- menopausal breast cancer. Int J Cancer 1995;62:266–270.
74.
Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO: Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 1997;76:1115–1118.
75.
Wolk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P, Adami HO, Trichopoulos D: Insulin-like growth factor 1 and prostate cancer risk: A population- based, case-control study. J Natl Cancer Inst 1998;90:911–915.
76.
Colao A, Marzullo P, Ferone D, Spiezia S, Cerbone G, Marino V, di Sarno A, Merola B, Lombardi G: Prostatic hyperplasia: an unknown feature of acromegaly. J Clin Endocrinol Metab 1998;83:775–779.
77.
Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ: Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999;91:620–625.
78.
Guevara-Aguirre J, Rosenbloom AL, Fielder PJ, Diamond FBJ, Rosenfeld RG: Growth hormone receptor deficiency in Ecuador: Clinical and biochemical phenotype in two populations. J Clin Endocrinol Metab 1993;76:417–423.
79.
Woods KA, Dastot F, Preece MA, Clark AJL, Postel-Vinay M-C, Chatelain PG, Ranke MB, Rosenfeld RG, Amselem S, Savage MO: Phenotype:genotype relationship in growth hormone insensitivity syndrome. J Clin Endocrinol Metab 1997;82:3529–3535.
80.
Goddard AD, Dowd P, Chernausek S, Geffner M, Gertner J, Hintz R, Hopwood N, Kaplan S, Plotnick L, Rogol A, Rosenfeld R, Saenger P, Mauras N, Hershkopf R, Angulo M, Attie K: Partial growth-hormone insensitivity: the role of growth hormone receptor mutations in idiopathic short stature. J Pediatr 1997;131:S51–S55.
81.
Coterill AM, Camacho-Hübner C, Duquesnoy P, Savage MO: Changes in serum IGF-I and IGFBP-3 concentrations during the IGF-I generation test performed prospectively in children with short stature. Clin Endocrinol 1998;48:719–724.
82.
Lee PDK, Wilson DM, Rountree L, Hintz RL, Rosenfeld RG: Efficacy of insulin-like growth factor I levels in predicting the response to provocative growth hormone testing. Pediatr Res 1990;27:45–51.
83.
Rosenfeld RG, Wilson DM, Lee PDK, Hintz RL: Insulin-like growth factors I and II in evaluation of growth retardation. J Pediatr 1986;109:428–433.
84.
Hasegawa Y, Hasegawa T, Aso T, Kotoh S, Nose O, Ohyama Y, Araki K, Tanaka T, Saisyo S, Yokoya S, Nishi Y, Miyamoto S, Sasaki N, Kurimoto F, Stene M, Tsuchiya Y: Clinical utility of insulin-like growth factor binding protein-3 in the evaluation and treatment of short children with suspected growth hormone deficiency. Eur J Endocrinol 1994;131:27–32.
85.
Adan L, Souberbielle J-C, Brauner R: Diagnostic markers of permanent idiopathic growth hormone deficiency. J Clin Endocrinol Metab 1994;78:353–358.
86.
Blum WF, Ranke MB, Kietzmann K, Gauggel E, Zeisel HJ, Bierich JR: A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin-binding protein: its use for diagnosis of GH deficiency. J Clin Endocrinol Metab 1990;70:1292–1298.
87.
Juul A, Skakkebæk NE: Prediction of the outcome of growth hormone provocative testing in short children by measurement of serum levels of insulin-like growth factor I and insulin- like growth factor binding protein 3. J Pediatr 1997;130:197–204.
88.
Cianfarani S, Boemi S, Spagnoli A, Cappa M, Argiro G, Vaccaro F, Manca Bitti ML, Boscherini B: Is IGF binding protein-3 assessment helpful for the diagnosis of GH deficiency? Clin Endocrinol 1995;43:43–47.
89.
Sklar C, Sarafoglou K, Whittam E: Efficacy of insulin-like growth factor binding protein 3 in predicting the growth hormone response to provocative testing in children treated with cranial irradiation. Acta Endocrinol 1993;129:511–515.
90.
Tillmann V, Buckler JMH, Kibirige MS, Price DA, Shalet SM, Wales JKH, Addison MG, Hill MS, Whatmore AJ, Clayton PE: Biochemical tests in the diagnosis of childhood growth hormone deficiency. J Clin Endocrinol Metab 1997;82:531–535.
91.
Hoffman DM, O’Sullivan AJ, Baxter RC, Ho KKY: Diagnosis of growth-hormone deficiency in adults. Lancet 1994;343:1064–1068.
92.
de Boer H, Blok G-J, Popp-Snijders C, van der Veen EA: Diagnosis of growth hormone deficiency in adults. Lancet 1994;343:1645–1646.
93.
Attanasio AF, Lamberts SWJ, Matranga AMC, Birkett MA, Bates PC, Valk NK, Hilsted J, Bengtsson B-Å, Strasburger CJ, and The Adult Growth Hormone Deficiency Study Group: Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. J Clin Endocrinol Metab 1997;82:82–88.
94.
Jørgensen JOL, Pedersen SA, Thuesen L, Jørgensen J, Ingemann-Hansen T, Skakkebæk NE, Christiansen JS: Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1989;i:1221–1225.
95.
Salomon F, Cuneo RC, Hesp R, Sönksen PH: The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989;321:1797–1803.
96.
de Boer H, Blok GJ, Popp-Snijders C, Stuurman L, Baxter RC, van der Veen E: Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers. J Clin Endocrinol Metab 1996;81:1371–1377.
97.
Janssen YJH, Frölich M, Roelfsema F: A low starting dose of genotropin in growth hormone deficient adults. J Clin Endocrinol Metab 1997;82:129–135.
98.
Lucidi P, Lauteri M, Laureti S, Celleno R, Santoni S, Volpi E, Angeletti G, Santeusanio F, de Feo P: A dose- response study of growth hormone (GH) replacement on whole body protein and lipid kinetics in GH-deficient adults. J Clin Endocrinol Metab 1998;83:353–357.
99.
Toogood AA, Shalet SM: Growth hormone replacement therapy in the elderly with hypothalamic-pituitary disease: a dose-finding study. J Clin Endocrinol Metab 1999;84:131–136.
100.
Johansson G, Rosén T, Bengtsson B-Å: Individualized dose titration of growth hormone (GH) during replacement in hypopituitary adults. Clin Endocrinol 1997;47:581.
© 1999 S. Karger AG, Basel
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.